Eledon Net Income Per Share from 2010 to 2026
| ELDN Stock | USD 2.09 0.04 1.88% |
Net Loss | First Reported 2010-12-31 | Previous Quarter (0.67) | Current Value (0.70) | Quarterly Volatility 437.0058281 |
Check Eledon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eledon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 433.5 K, Interest Expense of 1 M or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 9.0E-4 or PTB Ratio of 1.6. Eledon financial statements analysis is a perfect complement when working with Eledon Pharmaceuticals Valuation or Volatility modules.
Eledon | Net Income Per Share | Build AI portfolio with Eledon Stock |
Evaluating Eledon Pharmaceuticals's Net Income Per Share across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Eledon Pharmaceuticals's fundamental strength.
Latest Eledon Pharmaceuticals' Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Eledon Pharmaceuticals over the last few years. It is Eledon Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eledon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend |
|
Net Income Per Share |
| Timeline |
Eledon Net Income Per Share Regression Statistics
| Arithmetic Mean | (194.04) | |
| Coefficient Of Variation | (225.21) | |
| Mean Deviation | 248.39 | |
| Median | (28.11) | |
| Standard Deviation | 437.01 | |
| Sample Variance | 190,974 | |
| Range | 1.8K | |
| R-Value | 0.28 | |
| Mean Square Error | 188,110 | |
| R-Squared | 0.08 | |
| Significance | 0.28 | |
| Slope | 23.95 | |
| Total Sum of Squares | 3.1M |
Eledon Net Income Per Share History
About Eledon Pharmaceuticals Financial Statements
Eledon Pharmaceuticals investors utilize fundamental indicators, such as Net Income Per Share, to predict how Eledon Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | (0.67) | (0.70) |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eledon Stock
| 0.57 | GNLX | Genelux Common | PairCorr |
| 0.53 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.38 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.38 | KURA | Kura Oncology | PairCorr |
| 0.35 | LRMR | Larimar Therapeutics | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Eledon Pharmaceuticals Correlation against competitors. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could Eledon diversify its offerings? Factors like these will boost the valuation of Eledon Pharmaceuticals. Projected growth potential of Eledon fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eledon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Eledon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eledon's accounting equity. The concept of intrinsic value - what Eledon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Eledon Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eledon Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eledon Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eledon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.